Advertisements

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Category: press-releasesSource: businesswireindiaMar 20th, 2017

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease.....»»

Category: press-releasesSource: businesswireindiaDec 7th, 2016

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain

Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain.....»»

Category: press-releasesSource: businesswireindiaMay 11th, 2016

Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung

Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung.....»»

Category: press-releasesSource: businesswireindiaApr 7th, 2016

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients.....»»

Category: press-releasesSource: businesswireindiaDec 5th, 2016

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016

New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients

New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients.....»»

Category: press-releasesSource: businesswireindiaNov 8th, 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease.....»»

Category: press-releasesSource: businesswireindiaSep 10th, 2016

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD.....»»

Category: press-releasesSource: businesswireindiaSep 6th, 2016

Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment

Simple blood test combined with exacerbation history may help to identify when to add ICS to COPD treatment.....»»

Category: press-releasesSource: businesswireindiaSep 6th, 2016

Air pollution reduces life span of lung cancer patients: Study

Air pollution reduces life span of lung cancer patients: Study.....»»

Category: economySource: business-standardAug 7th, 2016

INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients

INMARKTM now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients.....»»

Category: press-releasesSource: businesswireindiaJun 30th, 2016

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases.....»»

Category: press-releasesSource: businesswireindiaJun 8th, 2016

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases

Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases.....»»

Category: press-releasesSource: businesswireindiaJun 8th, 2016

Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib

Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib.....»»

Category: press-releasesSource: businesswireindiaJun 2nd, 2016

IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease

IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease.....»»

Category: press-releasesSource: businesswireindiaMay 25th, 2016

Boehringer Ingelheim andBioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

Boehringer Ingelheim andBioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing.....»»

Category: press-releasesSource: businesswireindiaMay 23rd, 2016